Trials / Completed
CompletedNCT04726956
A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC
A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of Pancreatic Ductal Adenocarcinoma：A Multicenter Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 258 (actual)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to clarify the diagnostic significance of AKR1B10 in patients with pancreatic ductal adenocarcinoma, and to combine with CA19-9 to improve the diagnosis rate of pancreatic ductal adenocarcinoma.
Conditions
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2021-12-31
- Completion
- 2022-02-01
- First posted
- 2021-01-27
- Last updated
- 2024-10-16
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04726956. Inclusion in this directory is not an endorsement.